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Leber hereditary optic neuropathy (LHON) is due primarily to one of three common point mutations of mitochondrial
DNA (mtDNA), but the incomplete penetrance implicates additional genetic or environmental factors in the patho-
physiology of the disorder. Both the 11778GrA and 14484TrC LHON mutations are preferentially found on a speciﬁc
mtDNA genetic background, but 3460GrA is not. However, there is no clear evidence that any background inﬂuences
clinical penetrance in any of these mutations. By studying 3,613 subjects from 159 LHON-affected pedigrees, we show
that the risk of visual failure is greater when the 11778GrA or 14484TrC mutations are present in speciﬁc subgroups
of haplogroup J (J2 for 11778GrA and J1 for 14484TrC) and when the 3460GrA mutation is present in haplogroup K.
By contrast, the risk of visual failure is signiﬁcantly less when 11778GrA occurs in haplogroup H. Substitutions on
MTCYB provide an explanation for these ﬁndings, which demonstrate that common genetic variants have a marked
effect on the expression of an ostensibly monogenic mtDNA disorder.
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Leber hereditary optic neuropathy (LHON [MIM 535000])
is a common cause of maternally inherited visual failure
that affects at least 1 in 14,000 males.1 LHON typically
presents during young adulthood with dyschromatopsia
followed by a subacute painless loss of vision in one eye,
with symptoms developing in the other eye 6–12 wk after
the initial onset.2,3 In 195% of cases, LHON is due pri-
marily to one of three point mutations of mtDNA that
affect genes coding for different subunits of complex I of
the mitochondrial respiratory chain: 3460GrA in MTND1,
11778GrA in MTND4, and 14484TrC in MTND6.4 How-
ever, not all individuals who inherit a primary LHON
mtDNAmutation will develop the optic neuropathy,which
indicates that additional environmental or genetic factors
are important in the etiology of the disorder.3,5,6
Numerous anecdotal reports have linked the onset of
blindness with various environmental insults, including
excess alcohol consumption and smoking.7,8 In addition,
the analysis of large pedigrees followed over decades sug-
gests that the penetrance of the primary LHONmutations
may be decreasing in some families, possibly through an
improved diet and reduced tobacco and alcohol consump-
tion.9 However, rigorous cross-sectional epidemiological
studies reached different conclusions,10 and the role of
environmental agents has yet to be established.
By contrast, evidence supporting an additional genetic
inﬂuence is more compelling. Although the majority of
individuals with LHON inheritmutatedmtDNAonly from
their mother and thus are homoplasmic for the primary
mtDNA LHON mutation, some subjects harbor a mixture
of mutated and wild-type mtDNA (heteroplasmy).1,4 Ret-
rospective studies suggest that the risk of visual failure is
reduced in family members with !60% mutated mtDNA
in their blood.11,12 Heteroplasmy cannot, however, explain
the marked sex bias in LHON, which affects predomi-
nantly males. Segregation analysis is consistent with an
interacting recessive X-chromosomal locus in some fam-
ilies,13 which is supported by the results of genetic linkage
analysis implicating an ∼6-cM region of the X chromosome
that is likely to contain an interacting nuclear modi-
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Table 1. Haplogroup Frequencies for the 3,613 Subjects
with the 11778GrA, 14484TrC, and 3460GrA Mutations
mtDNA
Haplogroupa
No. (%) of Subjects with
11778GrA 14484TrC 3460GrA Total
H 927 (44) 2 (!1) 307 (47) 1,236 (34)
J 593 (28) 840 (99) 169 (26) 1,602 (44)
K 101 (5) … 75 (11) 176 (5)
M 3 (!1) … … 3 (!1)
T 87 (4) … … 87 (2)
U (without K) 184 (9) … 27 (4) 211 (6)
V … … 41 (6) 41 (1)
W 11 (!1) … … 11 (!1)
X 135 (6) 9 (1) … 144 (4)
Other 63 (3) … 39 (6) 102 (3)
Total 2,104 851 658 3,613
a There were no haplogroup I families.
ﬁer.14 Finally, there is a well-established strong association
between the mtDNA genetic background and both the
11778GrAand14484TrCmutationsbutnot3460GrA.15,16
mtDNA is inherited through the maternal line, is highly
polymorphic, and can be divided into haplogroups on the
basis of the presence of speciﬁc combinations of distin-
guishing mutations scattered throughout its entire se-
quence. mtDNAs belonging to the same haplogroup de-
rive by descent from the same ancestral female, as revealed
by the sharing of the distinguishing mutational motif.17,
18 Meta-analysis of the available data has shown that in-
dividuals with the 14484TrC mutation are 127-foldmore
likely to belong to western Eurasian haplogroup J than are
control subjects and that individuals with the 11778GrA
mutation are 13-fold more likely to belong to haplogroup
J than are control subjects.19 This has been observed in
different western Eurasian populations in genetically dis-
tinct pedigrees, which indicates that this is not a founder
effect.15,20 The reasons for the association are not clear, but
the association may relate to functional variants in the
MTCYB gene interacting synergistically with the primary
LHON mutation, leading to further compromise of com-
plex I function.21 If this is the case, then the clinical pene-
trance of both the 11778GrA and the 14484TrC muta-
tions should be increased on a haplogroup J background—
but this hypothesis has not been formally tested. Intri-
guingly, in one pedigree, 14484TrC had a low penetrance
on a haplogroup H background,9 which raises the possi-
bility that other mtDNA haplogroups might alter pene-
trance of the primary LHON mutations in a mutation-
speciﬁc manner.
The three primary LHON mutations were identiﬁed al-
most 2 decades ago, but, despite major advances in our
understanding of themolecular pathophysiology of LHON,
clinical management has remained largely the same. Mo-
lecular genetic testing and genetics counseling based on
empirical recurrence risks have changed little in the past
decade. Given the potential role of mtDNA haplotypes
in the penetrance of LHON, we performed a multicenter
study of 3,613 subjects from 159 different families trans-
mitting the 3460GrA, 11778GrA, and 14484TrC muta-
tions. By deﬁning the role of each haplogroup in LHON,
we hoped to improve the accuracy of genetics counseling
for LHONand also to advance ourunderstandingofmtDNA
genetic variation and its role in complex disease. Using
this approach, we also formally explored the possibility
that the penetrance of LHON is changing over time.
Material and Methods
Pedigrees were identiﬁed through a pan-European collaboration
and were anonymously entered into a central database. To min-
imize ascertainment bias, we did not analyze singleton cases (i.e.,
pedigrees with one affected individual). Extensive pedigree anal-
ysis was performed at each center. Sibships were included only if
there was one affected individual and/or the mother harbored a
primary LHON mtDNA mutation. The clinical phenotype was
determined by a local ophthalmologist. Unaffected individuals
had no visual symptoms. Previous studies have included unaf-
fected subjects only if they had no symptoms after reaching a
speciﬁc age (typically 30 years, given the median age of ∼24 years
for visual failure in LHON). This would, however, introduce an
ascertainment bias into a study of this type, since only affected
individuals aged !30 years old would be included, elevating the
penetrance value. We therefore included all subjects, irrespective
of age, to assess the lifetime penetrance of the disorder. The pri-
mary aim of this study was to determine the effect of mtDNA
haplogroups on clinical penetrance, andwe had no a priori reason
to think that this would be inﬂuenced by the age of subjects.
The diagnosis was conﬁrmed in all studied affected individuals
by direct sequencing of theMTND genes or by PCR-RFLP analysis.
For the purposes of this study, we did not accurately quantify
heteroplasmy, and we classiﬁed sibships only as either (1) ho-
moplasmic, if the mother was shown to be homoplasmic by an
established technique, or (2) heteroplasmic, if one member of the
nuclear family had been shown to be heteroplasmic. Retrospec-
tive analysis omitting the heteroplasmic sibships did not inﬂu-
ence the overall conclusions. mtDNA-haplogroup analysis was
performed either by PCR-RFLP analysis or by direct sequencing
of the mtDNA coding or control regions.16 Haplogroup J suban-
alysis was performed by direct sequencing across nucleotide po-
sitions 3010 (3010A in J1) and 15257 (15257A in J2), as described
elsewhere.21
We identiﬁed 3,613 individuals, including affected and unaf-
fected subjects, harboring a primary LHONmutation (11778GrA
[ , 58.2%]; 14484TrC [ , 23.6%]; 3460GrAnp 2,104 np 851
[ , 18.2%]) from 159 genealogically independent pedi-np 658
grees (11778GrA [ , 56.6%]; 14484TrC [ , 20.8%];np 90 np 33
3460GrA [ , 22.6%]). Of the subjects, 48.9% were malenp 36
(95% , including affected and unaffectedCIp 47.3%–50.6%
males). These proportions are in concordance with those of other
published smaller series.4 The mtDNA-haplogroup distribution
for each mtDNA LHON mutation is shown in table 1 and reﬂects
the well-established overrepresentation of haplogroup J in Eu-
ropean LHON-affected pedigrees. The complete data set is shown
in table 2. The sex was not known for four subjects who all be-
longed to the same 11778GrA haplogroup H family. Of the sib-
ships, 4.6% harbored at least one heteroplasmic individual.
Binary logistic regression was used to determine, simultane-
ously across the whole cohort, which variables inﬂuence the risk
of developing visual failure. This approach reduces the chance of
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Table 2. Haplogroup Distribution of Affected and Unaffected Subjects with
the 11778GrA, 14484TrC, and 3460GrA Mutations
Sex and mtDNA
Haplogroup
No. of Subjects with Mutation
11778GrAa 14484TrC 3460GrA
Unaffected Affected Unaffected Affected Unaffected Affected
Male:
H 289 155 1 … 112 36
J1 127 79 206 172 35 20
J2 34 36 38 18 15 16
K 30 17 … … 18 15
T 21 25 … … … …
U (without K) 51 36 … … 8 4
V … … … 19 3
W 2 1 … … … …
X 48 21 3 2 … …
Other 21 11 … … 16 4
Total 623 381 248 192 223 98
Female:
H 437 42 1 … 141 18
J1 185 27 292 25 53 6
J2 90 15 86 3 22 2
K 47 7 … … 31 11
T 40 1 … … … …
U (without K) 86 11 … … 14 1
V … … … … 17 2
W 5 3 … … … …
X 62 4 4 … … …
Other 28 6 … … 15 4
Total 980 116 383 28 293 44
a The sex was not known for four subjects (not included in the table), all belonging to the
same 11778GrA haplogroup H family.
Table 3. Major Factors Inﬂuencing the Clinical
Penetrance of the 11778GrA, 14484TrC, and
3460GrA Mutations in 3,613 Subjects
Variable P OR 95% CI
Sex 769.27# 10 5.41 4.52–6.48
LHON mutation .70
Heteroplasmy 41.37# 10 .37 .22–.62
Pedigree generation .26 .97 .90–1.01
type I error (false-positive result) and controls for differences in
the frequency of key variables among the different groups. Visual
failure was the dependent variable in the model, with the fol-
lowing independent categorical variables: sex, primary LHON
mtDNA mutation (modeled as a single categorical variable), pres-
ence of heteroplasmy, and mtDNA haplogroup. Since each hap-
logroup is an independent categorical variable associated with a
different cluster of haplotype-speciﬁc polymorphisms, we intro-
duced each haplogroup separately into the regression equation
while including all of the other potential confounding variables.
We studied only haplogroups present at 11% frequency across
the whole study group, in keeping with the “rule of thumb”
whereby logistic regression should be performed only when the
number of study subjects is 1 order of magnitude greater than
the number of parameters under study. To test the hypothesis
that the penetrance of primary LHON mutations has decreased
over the generations, we coded the present generation 1 and pre-
vious generations 2, 3, , thus allowing us to include sibship4…n
generation as a continuous variable in the logistic-regression
model. If the penetrance of LHON were changing with subse-
quent generations, the model would identify a signiﬁcant direct
correlation between penetrance and generation number.
Results
Before studying the mtDNA haplogroups, we initially in-
vestigated the effects of the other variables on the risk of
visual failure (table 3). As expected, the strongest predictor
of visual failure was sex, which was associated with a 5.41-
fold increased risk of blindness for males compared with
females. In addition, mtDNA heteroplasmywas associated
with a 0.37-fold reduced risk of visual failure when com-
pared with homoplasmic pedigrees. By contrast, there was
no difference in the risk of visual failure for the different
LHON mtDNA mutations ( ) nor any evidence toPp .70
support a change in penetrance in different generations
( ).Pp .26
Given thewell-establishedmutation-speciﬁcassociation
with mtDNA haplogroup J,19 we studied separately the
effect of common mtDNA haplogroups on the risk of
visual failure for each LHON mtDNA mutation (see table
4 for the results of the logistic regression and table 2 for
the complete data set). For 11778GrA, the risk of visual
failure was increased for pedigrees with a haplogroup J
background ( ; odds ratio ; 95%Pp .02 [OR]p 1.31 CIp
) but was reduced in pedigrees with a haplo-1.03–1.65
group H background ( ; ; 95%Pp .04 ORp 0.79 CIp
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Table 4. Effect of mtDNA Haplogroups on the Clinical
Penetrance of the 11778GrA, 14484TrC, and 3460GrA
Mutations
Mutation and
mtDNA Haplogroup P OR 95% CI
11778GrA:
H .04 .79 .63–.98
J .02 1.31 1.03–1.65
K .97 .99 .60–1.63
T .31 1.30 .79–2.14
U (without K) .59 1.11 .76–1.60
X .05 .62 .39–1.0
14484TrC:
H 1.0 91.49# 10 0
J .40 2.06 .40–10.66
X .60 .64 .12–3.53
3460GrA:
H .14 .72 .47–1.11
J .34 1.24 .80–1.90
K 32.35# 10 2.37 1.36–4.13
U (without K) .60 .76 .27–2.10
NOTE.—Binary logistic-regression model with visual failure as the de-
pendent variable. The following independent variables were included in
each model: sex, presence of heteroplasmy, and pedigree generation
(see table 1). The effect of the major European mtDNA haplogroups was
modeled in turn, adding each sequentially to the logistic-regression
equation. No 14484TrC pedigrees belonged to haplogroups K, T, or U,
and no 3460GrA pedigrees belonged to haplogroup T or X.
). For 3460GrA, the risk of visual failure was0.63–0.98
increased in pedigrees with a haplogroup K background
( ; ; 95% ).3Pp 2.35# 10 ORp 2.37 CIp 1.36–4.13
We were initially surprised that the analysis did not iden-
tify an association between 14484TrC and haplogroup J
(table 4). However, the lack of increased risk of visual fail-
ure among the 840 subjects with the 14484TrCmutation
on haplogroup J is most likely to be a consequence of the
virtual absence of non-J pedigrees (only 11 subjects, ∼1%)
(table 1). Given the fact that haplogroup J frequencies are
in the range of 3%–15% in European populations,22 the
99% frequency of 14484TrC on J mtDNAs observed in
this study (table 1) strongly suggests that the clinical pen-
etrance of the 14484TrC mutation is close to zero when
occurring on European mtDNA backgrounds other than
J. The 14484TrC mutation and the pedigrees in which it
occurs remain undetected simply because LHON does not
show up in the family when the mtDNA belongs to a non-
J haplogroup. This scenario is supported by the ﬁnding of
a U8b mtDNA harboring the 14484TrC mutation in the
course of a random survey of U mtDNAs from unaffected
subjects.23 Moreover, recent work has also shown that the
preferential association between LHON-affected pedigrees
with the 14484TrC mutation and J is attributable largely
to J1, a speciﬁc subgroup of haplogroup J.21 We therefore
compared the clinical penetrance of the 14484TrC mu-
tation on the J1 background with that on the J2 back-
ground. We observed a 1.85-fold increased risk of visual
failure for J1 relative to J2 ( ; 95%2Pp 2.3# 10 CIp
), in agreement with the observation that 28.3%1.09–3.15
of the J1 subjects versus only 14.5% of the J2 subjects are
clinically affected (table 1). The same kind of comparison
(J2 vs. J1) was performed for the 11778GrA mutation. In
that case, the situation was just the opposite, with J2 har-
boring a 1.73-fold increased risk of visual failure (Pp
; 95% ) relative to J1.21.7# 10 CIp 1.10–2.72
Discussion
By studying 3,613 individuals from 159 pedigrees, we pro-
vide the ﬁrst clear evidence that different mtDNA haplo-
groups inﬂuence the clinical penetrance of the three pri-
mary LHON mtDNA mutations. We made four principal
observations: (1) the penetrance of 14484TrC is increased
on a haplogroup J background, most prominently on the
J1 subhaplogroup; (2) the penetrance of 11778GrA is also
increased on a haplogroup J background, but, for this mu-
tation, the effect is most prominent on the J2 subhaplo-
group; (3) the penetrance of 11778GrA is reduced on a
haplogroup H background; and (4) the penetrance of
3460GrA is increased on a haplogroup K background.
The increased penetrance of 14484TrC and 11778GrA
on different J subhaplogroups is in keeping with previous
haplogroup-association studies reporting an increased fre-
quency of haplogroup J1 in 14484TrC pedigrees and an
increased frequency of J2 in 11778GrA pedigrees.21 It is,
however, most intriguing that closely related subhaplo-
types appear to have different effects on the twomost com-
mon LHON mtDNA mutations. For 3460GrA, the most
striking novel ﬁnding was the marked increased risk of
visual failure when the mutation was on the haplogroup
K background. This was not apparent in 11778GrA ped-
igrees, despite a greater number of subjects (table 1). In
keeping with this, haplogroup K subjects were overrepre-
sented in the 3460GrA group (11%, which is greater than
the frequency in most published European data sets22).
The 3460GrAmutationwas the least common in our sam-
ple (18% of subjects), and some haplogroups were not
represented (table 1), which limited statistical power and
our ability to conﬁdently interpret a slight tendency to-
ward increased penetrance of 3460GrA on haplogroup J2
and a reduced penetrance on haplogroup H. Finally, al-
though the reduced penetrance on a haplogroup H back-
ground has been described in a single 14484TrC family,9
this has not been described elsewhere for 11778GrA. To-
gether, these ﬁndings demonstrate that the clinical pene-
trance of LHON mtDNA mutations depends on the back-
ground mtDNA haplotype, implicating epistatic genetic
mechanisms that modulate the biochemical defect of
complex I that underpins the pathophysiology. How can
we explain these observations?
Relative to the root of the superhaplogroupR,haplogroup
H is deﬁned by the synonymous T7208C and A11719G,
the nonsynonymous T14766C in the cytochrome b gene
(MTCYB, cyt b I7T), and the 12S rRNA gene substitution
G2706A.24 Variation in the mtDNA rRNA genes can alter
susceptibility to the organ-speciﬁc nonsyndromic deafness
through a gene-environment interaction,25 and it is con-
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ceivable that different polymorphisms in the same gene
might reduce susceptibility to environmental precipitants
of the acute visual failure caused by LHON. Alternatively,
genetic variation in theMTCYB genemight be responsible.
Recent phylogenetic analysis has shown that MTCYB mu-
tations are overrepresented on both J1 and J2 subhaplo-
groups and that J1c and J2b are the principal clades re-
sponsible for the association with 11778GrA, whereas J1
is associated with 14484TrC.21 In addition to the 15452Cr
A substitution (MTCYB L236I) common to all haplogroup
J mtDNAs, J1c harbors an additional MTCYB substitution
(14798TrC/F18L), and J2b also carries two additional
MTCYB substitutions (15257GrA/D171Nand15812ArG/
V356M).21
Is this explanation consistent with the increased risk of
visual failure in 3460GrA families on a haplogroup K back-
ground? The MTND3 10398 reversion is shared by both
haplogroups J and K (and I) and has been proposed as
the functional variant responsible for the decreased risk
of Parkinson disease associated with these two haplo-
groups.26,27 However, like J1c, haplogroup K is deﬁned
by MTCYB 14798TrC/F18L, in keeping with the MTCYB
hypothesis explaining the haplogroup associations for
LHON.21 Although the association with MTCYB substitu-
tions could be a chance ﬁnding,21 recent evidence sup-
porting the existence of supercomplexes, consisting of
complex I and dimeric complex III,28 raises the possibility
that genetic variation in MTCYB might alter complex I
function, possibly by destabilizing the assembled super-
complex.29 Differences in the amino acid sequence of cyt
b (through subhaplogroup-speciﬁc polymorphisms),ND1,
ND4, and ND6 (through primary LHON mutations and
subhaplogroup-speciﬁc polymorphisms) could alter the
known physical interaction between complexes I and III,30
leading to the loss of complex I activity, as has been ob-
served in a patient with anMTCYBmutation.31–34 Likewise,
it is also conceivable that the I–III supercomplex could be
relatively stabilized by speciﬁc cyt b substitutions (in hap-
logroup H), although there is no experimental data to sup-
port this possibility at present. An alternative explanation
is that speciﬁc substitutions in MTCYB lead to a subtle
biochemical defect that adds to the systemic complex I
deﬁciency because of the primary LHON mutations af-
fecting complex I (MTND) genes.
Differences in the size of individual pedigrees are one
possible confounding factor in a study of this kind. To
minimize ascertainment bias, we excluded singleton cases
from this study. In addition, for the major haplogroup
effects, we obtained the same result when the study pop-
ulation was subdivided into small pedigrees (2–5 genera-
tions) or large pedigrees (15 generations). The lack of a
clear relationship between penetrance and the pedigree
generation is surprising, especially given the size of this
study and the extensive clinical data from a large number
of generations. The major improvement in the socioeco-
nomic scene in Europe and a corresponding improvement
in nutritional status imply that a simple improvement in
these variables is unlikely to reduce the penetrance of
LHON. This and other studies10 highlight the difﬁculty of
establishing a link between LHONandmajor environmen-
tal precipitants.
Given the marked geographic variation in speciﬁc
mtDNA subhaplogroups, it is conceivable that an associ-
ation may be important in one country but not another.
For example, the absence of J1c from the Iranian popu-
lation probably explains why the association between
LHON and haplogroup J is not seen in Iran.21 This poses
a challenge when it comes to genetics counseling and
highlights the importance of performing further studies
to determine the basis of the varied penetrance. We have
shown that a number of variables modulate the clinical
expression of LHON, and smaller studies should be inter-
preted with great caution, because of the possibility of
confounding factors. Deﬁning these factors will, however,
have a major impact on the clinical management of fam-
ilies transmitting this disorder.
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